תבנית:תרופה/אוורל 50 - Evorel 50
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ××× ×× ×× × ×ספ×× | |
|---|---|
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | G03CA Natural and semisynthetic estrogens, plain |
| ×ר××× ×¤×¢×× (ATC5) | Â
|
| צ×רת ××ª× | ×××-×¢××¨× - TRANSDERMAL |
| צ×רת ××× ×× | ×××ק×ת, PATCHES ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× |
| ×ת×××× | Deficiency symptoms by absence of Estrogen after the menopause or after surgical removal of the ovarians. They comprise hot flushes, insomnia, atrophies of the urogenital system, changes of mood and increasing loss of the bone substance, which can lead to osteoporosis. In women with intact uterus, estrogen substitution must always be supplemented with a sequential gestagen therapy.
|
| ת×× ×ת:× ×ª×× × ×¡×/תר×פ×/××××¨× 50 - Evorel 50 | |
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
  |
| ×¢××× ×צר×× |  |
|---|
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| ××××¨× 50 ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | - |
|---|---|
| ××××¢ ×רשת | - |
| ×©× ××¦×¨× | JANSSEN PHARMACEUTICA N.V.,BELGIUM |
| ×©× ××¢× ×ר×ש×× | J-C HEALTH CARE LTD |
| ר×ש××× | ת×ר×× ××ש×: 01/1996. ר×ש××× ×ת×ר××: 11/2011 |
| ת×ר×× ×¢×××× ××ר×× | 14/05/19 |
ת××× ×ª ×ר×××
××£ ×× × ×צר ×¢× ××× ××× ×××××ר ת×× ×ת ×¢× ×¤×¨×× ×תר×פ×.
- ××£ ×תר×פ×: ××××¨× 50 - Evorel 50
- ××ר××¡× ××× ×ת ×©× ×¤×¨×× ×תר×פ×: × ××ª× ×ער×× ×ת ××£ ×תר××¤× ××¢××. ×××××× ×××××¤× ×ת:
{{תר×פ×/××××¨× 50 - Evorel 50}}
×:
{{תר×פ×/××××¨× 50 - Evorel 50
| ×©× ×פר××ר=×¢×¨× ××ש (××רס ×ת ××¢×¨× ×©×××× ××××ר)
}}
השינוי האחרון נעשה בֹ־7 באפריל 2023 ב־16:32